Several clinical trials, currently in recruiting phase, in refractory or recurrent glioblastoma, are evaluating the safety, feasibility, dose and efficacy of B7-H3 CAR-T cells (NCT05835687, NCT06482905, NCT05366179 & NCT05474378 Table 2). This evidence concerns the gene CD276 and glioblastoma.